0.80
price up icon5.54%   0.042
pre-market  Pre-mercato:  .81   0.01   +1.25%
loading
Precedente Chiudi:
$0.758
Aprire:
$0.7693
Volume 24 ore:
129.25K
Relative Volume:
0.08
Capitalizzazione di mercato:
$5.08M
Reddito:
-
Utile/perdita netta:
$-17.06M
Rapporto P/E:
-0.0113
EPS:
-70.7173
Flusso di cassa netto:
$-14.18M
1 W Prestazione:
-3.82%
1M Prestazione:
-27.27%
6M Prestazione:
-85.32%
1 anno Prestazione:
-99.44%
Intervallo 1D:
Value
$0.734
$0.84
Intervallo di 1 settimana:
Value
$0.7303
$0.85
Portata 52W:
Value
$0.7303
$148.00

Cns Pharmaceuticals Inc Stock (CNSP) Company Profile

Name
Nome
Cns Pharmaceuticals Inc
Name
Telefono
1-800-946-9185
Name
Indirizzo
2100 WEST LOOP SOUTH, HOUSTON
Name
Dipendente
4
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-13
Name
Ultimi documenti SEC
Name
CNSP's Discussions on Twitter

Confronta CNSP con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CNSP
Cns Pharmaceuticals Inc
0.80 5.08M 0 -17.06M -14.18M -70.72
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.82 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
520.29 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.94 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.53 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
267.12 28.51B 3.81B -644.79M -669.77M -6.24

Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2020-12-28 Downgrade Ladenburg Thalmann Buy → Neutral
2020-08-24 Iniziato Ladenburg Thalmann Buy

Cns Pharmaceuticals Inc Borsa (CNSP) Ultime notizie

pulisher
Jun 12, 2025

Revolutionary Nasal Drug Delivery System Could Transform Treatment of Opioid Overdose and Epilepsy - Stock Titan

Jun 12, 2025
pulisher
Jun 12, 2025

Citadel Advisors LLC Takes Position in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

Jane Street Group LLC Boosts Stake in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - Defense World

Jun 10, 2025
pulisher
Jun 06, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit - Barchart.com

Jun 06, 2025
pulisher
Jun 06, 2025

CNS Pharmaceuticals Inc. to Showcase Glioblastoma Treatment Advancements at Brain Tumor Biotech Summit - citybuzz -

Jun 06, 2025
pulisher
Jun 05, 2025

CNSP: Insights on TPI 287's Promise at Brain Tumor Summit | CNSP Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit | CNSP Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Brain Cancer Breakthrough: New Drug Achieves 12 Responses in Glioblastoma Patients, FDA Grants Special Status - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit - Yahoo Finance

Jun 05, 2025
pulisher
May 22, 2025

CNS Pharmaceuticals (CNSP) Target Price Increased Amid Focus Shift to TPI-287 | CNSP Stock News - GuruFocus

May 22, 2025
pulisher
May 20, 2025

Late-Stage CNS Drug Developer Reviva Opens Access to Management at Benchmark and Lytham Conferences - Stock Titan

May 20, 2025
pulisher
May 19, 2025

CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved - Asianet Newsable

May 19, 2025
pulisher
May 16, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer - The Globe and Mail

May 16, 2025
pulisher
May 16, 2025

CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved By Stocktwits - Investing.com India

May 16, 2025
pulisher
May 16, 2025

CNS Pharmaceuticals (CNSP) Advances in Neuro-Oncology with Promi - GuruFocus

May 16, 2025
pulisher
May 16, 2025

CNSP Secures Funding to Support Operations Through 2026 | CNSP S - GuruFocus

May 16, 2025
pulisher
May 16, 2025

CNSP Secures Funding to Support Operations Through 2026 | CNSP Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update | CNSP Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

CNS Pharmaceuticals Secures $18M War Chest to Advance Breakthrough Brain Cancer Treatment - Stock Titan

May 16, 2025
pulisher
May 15, 2025

CNS Pharmaceuticals Raises $5M in Public Offering - TipRanks

May 15, 2025
pulisher
May 14, 2025

Health Care Stocks Face Broad Downturn As Sector Challenges Mount - Finimize

May 14, 2025
pulisher
May 14, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor - The Globe and Mail

May 14, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals sets terms for $5 million stock offering By Investing.com - Investing.com Canada

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications - The Globe and Mail

May 13, 2025
pulisher
May 13, 2025

Jazz Pharma. v. Avadel CNS Pharma: Federal Circuit Applies a Fact-Specific Approach to the Patent Infringement Safe Harbor - JD Supra

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Soars Over 100% on $5 Million Offering: What’s Driving the Surge? - RagingBull

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals sets terms for $5 million stock offering - Investing.com

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offer - GuruFocus

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | CNSP Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Stock Titan

May 13, 2025
pulisher
May 13, 2025

CNSP Gains Key Orphan Drug Designation Transfer for TPI 287 | CN - GuruFocus

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Acquires Orphan Drug Designation for TPI 287 in Glioblastoma - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals secures orphan drug status for cancer drug - Investing.com

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, - GuruFocus

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 | CNSP Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals secures orphan drug status for cancer drug By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 - Stock Titan

May 13, 2025
pulisher
May 13, 2025

Pre-market Movers: CNSP, XLO, PLRZ, SGMO... - RTTNews

May 13, 2025
pulisher
May 09, 2025

CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga

May 09, 2025
pulisher
May 07, 2025

Medical Patent Injunction At Odds With Hatch-Waxman, Federal Circuit Finds - Law360

May 07, 2025
pulisher
May 06, 2025

Clinical Trials Get a Legal Shield: Federal Circuit Reverses Pharma Patent Injunction - Patently-O

May 06, 2025
pulisher
Apr 29, 2025

Transneural Therapeutics Appoints CNS Drug Development Expert, Mark A. Demitrack, MD, as Chief Research and Development Officer - PR Newswire

Apr 29, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 23, 2025

CNSP stock touches 52-week low at $0.09 amid sharp decline - MSN

Apr 23, 2025
pulisher
Apr 15, 2025

CNSP stock touches 52-week low at $0.99 amid sharp decline - Investing.com

Apr 15, 2025
pulisher
Apr 14, 2025

10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey

Apr 14, 2025
pulisher
Apr 09, 2025

CNS Pharmaceuticals Advances TPI 287 for Glioblastoma - TipRanks

Apr 09, 2025
pulisher
Apr 06, 2025

CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020 - BioSpace

Apr 06, 2025
pulisher
Apr 05, 2025

Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP) - Defense World

Apr 05, 2025

Cns Pharmaceuticals Inc Azioni (CNSP) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.52
price down icon 1.06%
$35.91
price down icon 0.64%
$21.27
price up icon 1.67%
$104.85
price down icon 0.99%
$104.80
price down icon 0.28%
biotechnology ONC
$267.12
price up icon 0.12%
Capitalizzazione:     |  Volume (24 ore):